Bile Duct Cancer Market

• The Bile Duct Cancer Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• As per DelveInsight, the total diagnosed incident cases of Bile Duct Cancer were 46,466 in the 7MM in 2021, which are expected to grow during the study period, i.e., 2020–2034.
• Bile Duct Cancer epidemiology is segmented as Total Bile Duct Cancer Diagnosed-incidence Cases, Total Bile Duct Cancer Type-specific, Total Bile Duct Cancer Age-specific Cases, Total Bile Duct Cancer Stage-specific Cases, Total Bile Duct Cancer Mutation-specific Cases, and Total Treated Cases (across lines) of Bile Duct Cancer] in the Bile Duct Cancer market report.
• Bile duct cancer companies are actively investing in research and therapies to combat this rare malignancy. Key Bile duct cancer companies include AstraZeneca Plc, Bayer AG, Merck & Co Inc, and Advenchen Laboratories LLC, and others.
• In December 2024, the FDA granted orphan drug designation to PLT012 (Pilatus Biosciences) for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Experts highlight its potential against multiple tumors with unmet needs, with plans for its first US investigational new drug application submission and patient dosing in 2025.

Request for unlock CAGR of  Bile Duct Cancer Market

DelveInsight's "Bile Duct Cancer Market Insights, Epidemiology, and Market Forecast — 2034" report delivers an in-depth understanding of the Bile Duct Cancer, historical and forecasted epidemiology as well as the Bile Duct Cancer therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.

The Bile Duct Cancer market report provides current treatment practices, emerging drugs, Bile Duct Cancer market share of the individual therapies, current and forecasted Bile Duct Cancer market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current Bile Duct Cancer treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Bile Duct Cancer Disease Understanding

The DelveInsight’s Bile Duct Cancer market report gives a thorough understanding of Bile Duct Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Bile Duct Cancer, also known as Cholangiocarcinoma, is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile. Bile ducts connect your liver to your gallbladder and to your small intestine. Bile Duct tumors can arise from anywhere in the biliary tract and may be difficult to identify based on histopathologic analysis alone. Bile Duct Cancer can be anatomically differentiated into intrahepatic and extrahepatic Bile Duct Cancer.

Early research on the genetic pathophysiology of Bile Duct Cancer concentrated on determining the carcinogenic function of certain genes, which were frequently discovered to be mutated in other cancers or altered by copy number changes. Studies have demonstrated that the genetic profiles of intrahepatic Bile Duct Cancer and extrahepatic Bile Duct Cancer are diverse; in fact, 50% of patients have actionable mutations such as FGFR, IDH1, HER2, and BRAF.

Bile Duct Cancer Diagnosis

For a definitive diagnosis, patients usually undergo endoscopic retrograde cholangiopancreatography and procedures such as cytology, brushing, FISH (fluorescence in situ hybridization)-polisomy, biopsy, ultrasonography, choledochoscopy, cholangioscopy, chromoendoscopy, confocal endoscopy, narrow-band imaging. MRI devices, Computed Tomography (CT) Devices, endoscopic ultrasonography, or 18FDG PET-CT cannot definitively demonstrate the stricture’s neoplastic nature.

Bile Duct Cancer Treatment

Surgery with complete resection represents the only treatment for Bile Duct Cancer with curative intent. Other treatment approaches may include liver transplantation which is associated with rapid tumor recurrence and low survival, and it has historically not been recommended as a treatment for unresectable Bile Duct Cancer. Chemotherapy for patients presenting with unresectable or metastatic Bile Duct Cancer, systemic chemotherapy remains the mainstay palliative treatment modality, and the role of adjuvant chemotherapy is not clearly defined in Bile Duct Cancer, but for patients with local recurrence after resectioning pBile Duct Cancer, chemotherapy has been recommended. Bile duct cancer clinical trials are essential for discovering new treatments, improving patient outcomes, and advancing research in this rare and aggressive form of gastrointestinal cancer.

Bile Duct Cancer Epidemiology 

The Bile Duct Cancer epidemiology section provides insights about historical and current Bile Duct Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• As per DelveInsight, the total diagnosed incident cases of Bile Duct Cancer were 46,466 in the 7MM in 2021, which are expected to grow during the study period, i.e., 2020–2034.
• The disease epidemiology covered in the report provides historical as well as forecasted Bile Duct Cancer epidemiology [segmented as Total Diagnosed-incidence Cases of Bile Duct Cancer, Total Type-specific Cases of Bile Duct Cancer, Total Age-specific Cases of Bile Duct Cancer, Total Stage-specific Cases of Bile Duct Cancer, Total Mutation-specific Cases of Bile Duct Cancer, and Total Treated Cases (across lines) of Bile Duct Cancer] in the 7MM covering the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan from 2020 to 2034.

Country Wise- Bile Duct Cancer Epidemiology

This section provides glimpse of the Bile Duct Cancer epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Bile Duct Cancer Recent Developments 

• In December 2024, the FDA granted orphan drug designation to PLT012 (Pilatus Biosciences) for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Experts highlight its potential against multiple tumors with unmet needs, with plans for its first US investigational new drug application submission and patient dosing in 2025.

Bile Duct Cancer Drug Analysis

The drug chapter segment of the Bile Duct Cancer report encloses the detailed analysis of Bile Duct Cancer marketed drugs and late stage (Phase-III and Phase-II) Bile Duct Cancer pipeline drugs. It also helps to understand the Bile Duct Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases. Bile duct cancer pipeline drugs analysis explores emerging therapies targeting cholangiocarcinoma, assessing novel treatments, clinical trials, and future market trends. The Bile Duct Cancer drugs market is witnessing growth due to rising disease awareness, emerging targeted therapies, and increasing investment in oncology research aimed at improving patient outcomes and survival rates globally.

Bile Duct Cancer Marketed Drugs

TIBSOVO (ivosidenib): Servier

In August 2021, the FDA approved ivosidenib for adults with previously treated, locally advanced or metastatic Bile Duct Cancer (cholangiocarcinoma) with an isocitrate dehydrogenase-1 (IDH1) mutation. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. It was awarded Orphan Drug Designation for acute myeloid leukemia and for Bile Duct Cancer (Cholangiocarcinoma). 

TRUSELTIQ (infigratinib): Helsinn Healthcare

On May, 2021, the FDA granted accelerated approval to infigratinib, a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic Bile Duct Cancer (cholangiocarcinoma) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

PEMAZYRE (pemigatinib): Incyte

Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading. On April, 2020, the FDA granted accelerated approval to Pemazyre (pemigatinib), the first treatment approved for adults with locally advanced or metastatic Bile Duct Cancer (cholangiocarcinoma) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. 

Note: Detailed Current therapies assessment will be provided in the full report of Bile Duct Cancer...

Bile Duct Cancer Emerging Drugs

• KEYTRUDA (pembrolizumab) is being developed by Merck is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. It is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1, and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
• IMFINZI (durvalumab), is being developed by AstraZeneca. It is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses. It is known as a checkpoint inhibitor drug.
• ZW 25 (zanidatamab), being co-developed by Zymeworks and BeiGene, is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2, resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function mediated cytotoxicity, enhanced antibody internalization and HER2 downregulation and enhanced blockade of ligand-dependent and ligand-independent tumor growth.

Note: Detailed emerging therapies assessment will be provided in the full report of Bile Duct Cancer

Bile Duct Cancer Market Outlook

Most patients have an advanced or incurable illness when they are diagnosed, leaving systemic therapy as their sole choice for treatment. It is generally known that subgroups vary in their tumor biology and clinical presentation in addition to their varied etiological sources. Surgery may be curative for individuals with resectable illness when they first arrive, although these patients make up a small percentage with substantial recurrence rates. Additionally, the recurrence patterns often prohibit additional curative resection. 

The best method for extending survival is still total surgical resection; however, disease recurrence is not unheard of. Furthermore, patient comorbidities sometimes precluded surgical intervention, even if it could technically be done. Therefore, in order to increase survival in such a population, reduced morbidity interventional procedures must be developed.

Liver transplantation has been associated with rapid tumor recurrence and low survival and has historically not been recommended as a treatment for unresectable Bile Duct Cancer. In chemotherapy for patients presenting with unresectable or metastatic Bile Duct Cancer, systemic chemotherapy remains the mainstay palliative treatment modality. The role of adjuvant chemotherapy is not clearly defined in Bile Duct Cancer, but for patients with local recurrence after resectioning cholangiocarcinoma, chemotherapy has been recommended.

Photodynamic therapy can improve survival in patients with unresectable BTC. The role of radiation therapy in BTC is still not clearly outlined, but radiation with concurrent chemotherapy has been recommended in margin-positive and node-positive iCCA and pCCA, and unresectable pCCA is ineligible for liver transplantation. Although debated, various guidelines recommend that routine biliary drainage should be avoided before staging and assessment of resectability of Bile Duct Cancer and preoperatively.

The dynamics of the Bile Duct Cancer market is anticipated to change in the coming years owing to the advancement in diagnosis and proper understanding of the role of genetic aberrations, particularly in regions encoding key components of signaling pathways, allowing researchers to approach Bile Duct Cancer with new directions and make discoveries. Key players such as Merck, AstraZeneca, Zymeworks, and BeiGene, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences, Basilea Pharmaceutica and various others are involved in developing therapies for Bile Duct Cancer.

According to DelveInsight, the Bile Duct Cancer market in 7MM is expected to witness a major change in the study period 2020-2034.

Bile Duct Cancer Analyst Commentary

• The pipeline of Bile Duct Cancer is very robust, many potential therapies are being investigated for the treatment of Bile Duct Cancer, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Bile Duct Cancer market in the 7MM. Aside from that, the market size of Bile Duct Cancer may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
• The market growth of Bile Duct Cancer may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Bile Duct Cancer Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Bile Duct Cancer market or expected to get launched in the market during the study period 2020-2034. The analysis covers Bile Duct Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. 

Note: Detailed emerging therapies assessment will be provided in the full report of Bile Duct Cancer.

Bile Duct Cancer Pipeline Development Activities

The Bile Duct Cancer pipeline report provides insights into Bile Duct Cancer Clinical Trials within Phase II and Phase III stage. It also analyses Bile Duct Cancer key players involved in developing targeted therapeutics.

Bile Duct Cancer Clinical Trial Development Activities

The Bile Duct Cancer clinical trials analysis report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Bile Duct Cancer emerging therapies.

Bile Duct Cancer Market Reimbursement Scenario in Bile Duct Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views on Bile Duct Cancer

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Bile Duct Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Bile Duct Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Bile Duct Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Bile Duct Cancer Market Report

• The report covers the descriptive overview of Bile Duct Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Bile Duct Cancer epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Bile Duct Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Bile Duct Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Bile Duct Cancer market

Bile Duct Cancer Market Report Highlights

• In the coming years, the Bile Duct Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The Bile Duct Cancer companies and academics are working to assess challenges and seek opportunities that could influence Bile Duct Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Bile Duct Cancer. The launch of emerging therapies will significantly impact the Bile Duct Cancer market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bile Duct Cancer
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Bile Duct Cancer Market Report Insights

• Bile Duct Cancer Patient Based Market Forecasting
• Bile Duct Cancer Therapeutic Approaches
• Bile Duct Cancer Pipeline Analysis
• Bile Duct Cancer Market Size and Trends
• Bile Duct Cancer Market Opportunities
• Impact of Upcoming Bile Duct Cancer Therapies

Bile Duct Cancer Market Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Bile Duct Cancer Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Bile Duct Cancer Drugs Uptake

Bile Duct Cancer Market Report Assessment

• Bile Duct Cancer Current Treatment Practices
• Bile Duct Cancer Unmet Needs
• Bile Duct Cancer Pipeline Product Profiles
• Bile Duct Cancer Market Attractiveness
• Bile Duct Cancer Market Drivers
• Bile Duct Cancer Market Barriers

Key Questions Answered In The Bile Duct Cancer Market Report:

Bile Duct Cancer Market Insights:

• What was the Bile Duct Cancer drug class share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Bile Duct Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
• What are the key findings of the market across 7MM and which country will have the largest Bile Duct Cancer market size during the forecast period (2020-2034)?
• At what CAGR, the Bile Duct Cancer market is expected to grow by 7MM during the forecast period (2020-2034)?
• What would be the Bile Duct Cancer market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Bile Duct Cancer market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Bile Duct Cancer Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Bile Duct Cancer?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What is the historical Bile Duct Cancer patient pool in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• What would be the forecasted patient pool of Bile Duct Cancer in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Bile Duct Cancer?
• Out of all 7MM countries, which country would have the highest incident population of Bile Duct Cancer during the forecast period (2020-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2020-2034)?

Current Bile Duct CancerTreatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Bile Duct Cancer treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Bile Duct Cancer in the US, Europe, and Japan?
• What are the Bile Duct Cancer marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many Bile Duct Cancer companies are developing therapies for the treatment of Bile Duct Cancer?
• How many therapies are in-development by each company for Bile Duct Cancer treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Bile Duct Cancer treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bile Duct Cancer therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bile Duct Cancer and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Bile Duct Cancer?
• What are the global historical and forecasted markets of Bile Duct Cancer?

Reasons to buy Bile Duct Cancer Market Forecast Report

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Bile Duct Cancer market
• Organize sales and marketing efforts by identifying the best opportunities for Bile Duct Cancer in the US, Europe (Germany, Spain, Italy, and France) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Bile Duct Cancer market
• To understand the future market competition in the Bile Duct Cancer market